FDA Grants Priority Review to Palvella’s QTORIN Rapamycin as Potential First Treatment for Rare Lymphatic Malformations

FDA accepts Palvella’s QTORIN rapamycin NDA with Priority Review for microcystic lymphatic malformations. Target decision date is February 28, 2027.

FDA Grants Priority Review to Palvella’s QTORIN Rapamycin as Potential First Treatment for Rare Lymphatic Malformations
Credit: Palvella Therapeutics
Already have an account? Sign in.